These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 25897494)

  • 1. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
    Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
    PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.
    Hoogland AM; Jenster G; van Weerden WM; Trapman J; van der Kwast T; Roobol MJ; Schröder FH; Wildhagen MF; van Leenders GJ
    Mod Pathol; 2012 Mar; 25(3):471-9. PubMed ID: 22080055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
    BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
    Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
    Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
    Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas.
    Downes MR; Satturwar S; Trudel D; van der Kwast TH
    Pathol Res Pract; 2017 Jan; 213(1):34-38. PubMed ID: 27913052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.
    Kimura T; Furusato B; Miki J; Yamamoto T; Hayashi N; Takahashi H; Kamata Y; van Leenders GJ; Visakorpi T; Egawa S
    Pathol Int; 2012 Nov; 62(11):742-8. PubMed ID: 23121605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.
    Shah RB; Bentley J; Jeffery Z; DeMarzo AM
    Hum Pathol; 2015 May; 46(5):698-706. PubMed ID: 25724568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
    Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
    Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
    Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
    Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.
    Tsourlakis MC; Khosrawi P; Weigand P; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Krech T; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S
    Int J Mol Sci; 2015 Apr; 16(4):8591-606. PubMed ID: 25894226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
    Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
    Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
    Lahdensuo K; Erickson A; Saarinen I; Seikkula H; Lundin J; Lundin M; Nordling S; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
    Mod Pathol; 2016 Dec; 29(12):1565-1574. PubMed ID: 27562498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.